Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on the day's biggest business stories
Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
The Trump administration "definitely missed the window" to mass produce Regeneron Pharmaceuticals' coronavirus antibody drug this year, former FDA commissioner Scott Gottlieb told CBS News' "Face the Nation" on Sunday.
Why it matters: President Trump, who received the antibody cocktail after testing positive for the coronavirus, has hailed the drug as a miraculous "cure" — despite a lack of scientific evidence — and promised to distribute it to every hospital for free.
- The president is now seeking an emergency use authorization for the drug from the FDA.
- Regeneron CEO Leonard Schleifer said earlier in the show that the company currently only has enough doses for 50,000 patients. More than 50,000 Americans have tested positive for COVID-19 each of the past three days.
What he's saying: "We would have needed to take different steps in April and May to ramp up manufacturing capacity to have the drug available in larger quantities right now," Gottlieb said.
- "It's too late for this year. I think we could still take steps to do it for 2021, but we're stuck with the doses we have."
- Gottlieb said, "You'd probably need anywhere between 300,000 and 400,000 doses a month to supply it just for people who are indicated based on age alone," and he added that he and others raised the issue of ramping up manufacturing "many times" earlier in the year.